In Brief
To date, long recognition loops have been a hallmark of apex-targeting antibodies. Cale et al. identify a lineage of HIV-1-neutralizing antibodies that target the envelope trimer apex. The N90-VRC38 lineage uses a loop of average length-a feature that may make it a useful prototype for vaccine design.
INTRODUCTION
Neutralizing antibodies (NAbs) are likely to be a key component of effective HIV-1 vaccine immunity (Mascola and Montefiori, 2010) . NAbs interfere with HIV-1 infection by binding to envelope (Env) spikes (comprised of gp120/gp41 trimers) on virion surfaces, thereby blocking receptor engagement or membrane fusion (Overbaugh and Morris, 2012) . The glycan shield encasing these trimers helps the virus to evade NAbs, in part because carbohydrates are self-antigens to which antibody (Ab) responses are likely regulated by tolerance. Nevertheless, most, if not all, HIV-1 broadly neutralizing antibodies (bnAbs) make some glycan contacts upon native Env trimer binding (Stewart-Jones et al., 2016) .
HIV-1 vaccine candidates can induce autologous NAbs but largely fail to induce NAbs against other circulating (tier 2) strains (Crooks et al., 2015; de Taeye et al., 2015; McCoy and Weiss, 2013) . In contrast, cross-reactive NAbs develop in $50% of HIV-1 infections (Doria-Rose et al., 2010; Hraber et al., 2014) . Isolating monoclonal NAbs from such donors affords opportunities to understand how they develop and may be useful as vaccine blueprints (Burton and Hangartner, 2016) .
Monoclonal bnAbs fall into several epitope clusters that, together, cover most of the trimer surface Ward and Wilson, 2015) . The consistent features in different bnAbs suggest that a limited number of repertoire solutions can effectively tackle this complex antigen (Kwong and Mascola, 2012; Mascola and Haynes, 2013) . One group of bnAbs targets the gp120 V1V2 loop at the trimer apex and includes PG9/16, CH01-04, CAP256.VRC26.01-33, and PGT141-145/PGDM1400-1412 (Andrabi et al., 2015; Bonsignori et al., 2011; Doria-Rose et al., 2015; Gorman et al., 2016; McLellan et al., 2011; Moore et al., 2011; Pancera et al., 2010; Sok et al., 2014; Walker et al., 2009 Walker et al., , 2011 . These NAbs exhibit unusually long (> 24 amino acids [AA] by Kabat numbering) anionic third heavy chain complementarity determining regions (CDRH3) that are often tyrosine sulfated (legend continued on next page) (excluding CH01-04) and project outward to penetrate the glycan shield and contact underlying protein. Abs with long CDRH3s naturally occur at low frequency due to a need for unusual recombination events and due to their regulation by tolerance (Briney et al., 2012a (Briney et al., , 2012b Haynes et al., 2012) . Therefore, one goal of ongoing bnAb discovery is to identify NAbs with common repertoire features that are amenable to vaccine design. NAb recovery efforts have taken two approaches: one involves high-throughput screening of memory B cell micro-cultures that identified known V1V2-directed bnAbs (Bonsignori et al., 2011; Walker et al., 2011; Walker et al., 2009) ; a second approach is to label desirable memory B cells with fluorescent ''baits,'' followed by single-cell sorting and RT-PCR (Doria-Rose et al., 2015; Sok et al., 2014) . Here, we used virus-like particles (VLPs) that present trimers in a natural membrane context (Crooks et al., 2011 (Crooks et al., , 2015 Hicar et al., 2010) to probe memory B cells of a donor whose serum exhibited broad neutralization. We recovered a NAb lineage of moderate potency and breadth, N90-VRC38.01-11, that bound the V1V2 apex via an average length, non-protruding CDRH3, thereby revealing a new immunological solution to target the HIV-1 V1V2 apex site that may be more amenable for vaccine design.
RESULTS

VLPs Identify a New NAb Lineage with an Average-Length CDRH3
To develop VLPs as B cell probes, we co-transfected plasmids encoding SIV Gag, Env, Rev, and Gag-GFP ( Figure S1 ). Concentrated supernatants were protease digested, resulting in ''GFP-Trimer VLPs.'' SIV Gag and Gag-RFP plasmids were co-transfected to make ''RFP-bald VLPs'' as a counterstain. VLP labeling was verified using monoclonal Ab (mAb)-expressing Ramos cells and primary seronegative B cells ( Figure S1 ). VLPs were then used to probe donor N90 B cells, whose serum neutralizes in a pattern that did not track with known bnAbs (Georgiev et al., 2013; Huang et al., 2014) (Figure S2A ). Negatively selected N90 memory B cells were stained and gated for singlets, CD3 Figure S1G ). The extended positive shoulder imparted by trimer VLPs suggested specific labeling. We selected cells shown as green dots ( Figure 1B ). Despite a study in which VLPs recovered lipid-binding Abs (Hicar et al., 2010) , RFP-bald VLP counterstaining was weak. The difference could relate to the higher VLP dose used for staining that allowed stringent washing (Figures S1C and S1D) but may also relate to the relatively dim RFP signal ( Figure S1F ). Following cell lysis, heavy-and light-chain variable segments were RT-PCR amplified, sequenced, and aligned. We prioritized clones with NAb features: (1) > 10% divergence from germline VH (heavy chain variable domain) nucleotide sequence; (2) long CDRH3 loops; (3) repeated recovery; or (4) insertion and deletion mutations. Two related clones, VRC38.01 and VRC38.02 (dark green dots in Figure 1B ), were identified. To recover additional VRC38 relatives, a second sort used PElabeled BG505 SOSIP gp140 trimers (a near-native Env ectodomain mutant derived from the BG505 strain) as a positive probe. As VRC38.01 neutralizes the HIV-1 strain YU2 but does not bind to gp140F (a non-native, uncleaved Env ectodomain bearing a C-terminal foldon trimerization tag) derived from the same strain by ELISA ( Figures S2D and S2E ), APC-labeled YU2 gp140F trimers were used as a counterstain. PE + APC À sorting (Figure S1H) recovered nine more variants, VRC38.03-VRC38.11 (dark red dots in Figure 1C ), all of which show little or no gp140F binding (Figures S2D and S2E) . VRC38 variants had a 16 AA CDRH3 and a 10 AA CDRL3, diverged 15%-20% nucleotides from germline VH3-13 (Figure 1D) and neutralized 3%-42% of a multi-clade 31-member virus panel ( Figure 1E ). Geometric mean IC 50 titers (GMT) against sensitive viruses were 0.076-1.62 mg/mL. Although VRC38.09 was not as broad as VRC38.01, it neutralized one VRC38.01-resistant virus (X1632.S2.B10) ( Figures 1E and S2A ). We paired three VRC38 heavy-chain orphans from the second sort (Figure S2B ) with the VRC38.01 light chain, one of which, VRC38.14, neutralized a VRC38.01-resistant strain (ZA012.29). Combining all lineage members, breadth against the 31-member virus panel was 48%. The broadest clone, VRC38.01, neutralized 30% of a panel of 208 Env-pseudoviruses (Table S1 ) and did not react with host antigens, as measured by cardiolipin ELISA (Figure S2F) and Hep2 (human epithelial type 2) staining ( Figure S2G ). Despite the donor's North American origin and clade B infection , VRC38 NAbs potently neutralized several clade A and AE viruses.
Neutralization profiles ( Figure S2A ) suggested that VRC38-like NAbs were not a dominant contributor to serum breadth. Several viruses were sensitive to the N90 serum, but not to VRC38 clones. Purified N90 serum immunoglobulin G (IgG) did not compete with VRC38.01 for binding to JR-FL native flexibly linked (NFL) trimers ( Figure S2C ), further suggesting low prevalence (< 1mg/mL; Figure S2C ). Overall, the VRC38 lineage was infrequent in the donor plasma, exhibited 15%-20% germline divergence, modest neutralization potency and breadth, and no autoreactivity.
VRC38 Targets the V1V2-Trimer Apex VRC38.01's ability to neutralize the YU2 strain ( Figure 1E ), despite poor YU2 gp140F binding ( Figures S2D and S2E) , suggested a quaternary epitope. By ELISA, VRC38.01 competed strongly with V1V2 bnAbs for binding trimer VLPs and, to a lesser extent, with glycan-V3 bnAb PGT121 (Figure 2A V1V2 bnAbs, PGT121 and, to a modest extent, glycan-V3 bnAb PGT125 inhibited VRC38.01 binding ( Figure S3A ). Neutralization of the JR-FL strain without a E168K mutation ( Figure 1E ) suggested a distinct V1V2 binding mode. Unlike for VRC38.01, this mutation was crucial for other V1V2 Nabs, and in some cases (e.g., with PG9, PG16, and CH01), an N189A mutation was also needed for full sensitivity ( Figure S3B ) (Doores and Burton, 2010) . To assess quaternary epitope dependency, we compared binding to monomeric gp120 and trimeric SOSIPs of sensitive strains, Q23.17 and DU156.12. Like PGT145, VRC38.01 bound to trimers, but not monomers, whereas glycan-V3 bnAb PGT128 bound to both forms of Env ( Figure 2B ). PG9 bound to DU156.12, but not Q23.17 gp120 ( Figure 2B ). Further analysis revealed VRC38.01 and PG9 bound to gp120 monomers from several neutralization-sensitive strains ( Figure 2C ). Together, these data suggest that these mAbs exhibit quaternary epitope preference, but that this is not a strict requirement for binding.
The footprint of VRC38.01 Fab (fragment, antigen-binding) was examined on BG505 SOSIP trimers by negative-stain electron microscopy (EM, Figure 2D ). 2D class averages showed binding near the trimer apex. PG9 and CAP256-VRC26.09, for which 3D reconstructions were available (EMDB: 2241 and EMDB: 5856, respectively) appeared to straddle two gp120 protomers, binding adjacent to the 3-fold axis at a slightly offvertical angle. 2D views of complexes with Fabs PDGM1400 or VRC38.01 were insufficient for 3D modeling. Nevertheless, class averages suggested footprints, as indicated in Figure 2D . VRC38.01's footprint was farther from the 3-fold axis and showed little interprotomer overlap. Overall, these data showed that VRC38.01 targets the V1V2 apex with a quaternary epitope preference.
VRC38.01 Binds ''Off Center'' and at Less than 3:1 Stoichiometry V1V2 bnAbs typically bind the trimer with a stoichiometry of 1:1, in part because their footprints straddle gp120 protomers. 2D class averages of VRC38.01 Fab-trimer complexes by EM indicated one or two Fabs per trimer in $85% or $15% of cases, respectively ( Figure 2D ). Using VRC38.01 IgG, rather than the Fab, increased the proportion of complexes containing two Abs to 65% ( Figure 2D ), perhaps due to the increased avidity of two Fab arms; however, as the crystallizable fragment (Fc) of the IgGs was unresolved, it was unclear whether both Fabs originated from the same IgG in the EM images. Related to this point, VRC38.01 IgG was much more potent (17-to 170-fold) than its monovalent Fab, unlike PG9 (1-to 3.5-fold higher) and PGT145 (1-to 12-fold higher) ( Figure S4A ). Furthermore, real-time binding of VRC38.01 IgG to BG505 SOSIP trimers showed > 7-fold stronger binding over the Fab (Figure S4B ), also supporting the idea that VRC38.01 IgG may engage trimers with both Fab arms simultaneously.
Binding stoichiometry was investigated by three further methods. First, we checked bnAb-mediated native trimer mobility shifts. 2G12 bound progressively to trimers with increasing concentrations, providing a reference ladder (Figure S4C) . Saturating concentrations of all V1V2 NAbs bound at one copy per trimer ( Figure S4C ). In a second approach, we measured binding kinetics by biolayer interferometry (BLI). A standard curve was first generated with various trimer-NAb complexes of known ligand stoichiometries at saturation ( Figure S4D ). By interpolation, we inferred that $2 copies of VRC38.01 (Fab or IgG) occupied the trimer ( Figure S4D ). In a third approach, we performed isothermal titration calorimetry (ITC) to assess VRC38.01 Fab binding to the BG505 native, flexibly linked (NFL) trimer, resulting in an estimate of N = 2.26 ( Figure S4E ). Previously, one copy PG9 Fab resulted in N = 0.6-0.8 Sanders et al., 2013) , 2 copies of PGT151 Fab resulted in N = 1.3 (Blattner et al., 2014 ) and 3 copies of PGT121 or 2G12 Fabs binding per trimer gave N = 2.3-2.4 (Sanders et al., 2013) . Thus, an N value of 2.26 suggests that 2-3 VRC38.01 Fabs bind per trimer.
In addition to effects of avidity, the discrepancies above may relate to assay characteristics, with negative-stain EM and BN-PAGE emphasizing binding at equilibrium and BLI and ITC emphasizing on rate and maximum binding. Another contributing factor may be that the trimer strain and form differed between assays. Similar discrepancies were previously noted (Lee et al., 2015) . Collectively, our data suggest that VRC38.01 recognition occurs at a sub-saturating antibody:trimer stoichiometry ( Figures 2D and S4 ).
VRC38.01 Targets V1V2 Apex Glycans via a Non-protruding Loop
The off-center VRC38.01 footprint ( Figure 2D ), and its ability to neutralize viruses lacking a K168 residue ( Figure S3B ), suggested a unique binding mode. To obtain atomic-level detail, we co-crystallized Fab VRC38.01 with a V1V2-1FD6 scaffold (McLellan et al., 2011) derived from strain WITO.33. For reference, we first determined the unliganded VRC38.01 Fab structure to 1.6 Å , then we solved the complex structure to 3.5 Å by molecular replacement. Refinement yielded an R work , R free of 17.3, 20.2 and 21.3, 27.2 for the unliganded Fab and co-crystal structures, respectively ( Figures 3A-3C , S5A, and Table S2 ). No significant binding-induced conformational changes were observed ( Figures 3B, 3C , and S5A). Overall, these structures revealed V1V2 loop binding via protein-protein side-chain interactions with strands A, B, and C and extensive N156 and N160 glycan binding (Figures 3 and S5A ).
The V1V2 domain formed a 5-stranded b barrel as observed for near-native BG505 Env trimers Stewart-Jones et al., 2016) , with a root-mean-square deviation (RMSD) of 1.1 Å across the b-strand residues ( Figure 3C ). Extensive VRC38.01-N-linked glycan contacts had buried surface areas of 490 Å 2 and 545 Å 2 for N156 and N160 glycans, respectively ( Figures 3D and 3E ). Mutations revealed that VRC38.01 was critically dependent on glycan N156 and heavily dependent on glycan N160 ( Figure S5B ). Minor contacts were observed between the light chain and glycan N133 (Figures 3A and 3E) . Protein-protein contacts accounted for 470 Å 2 of buried surface area, including three hydrogen bonds and two salt bridges between V1V2 and the VRC38.01 heavy chain ( Figure S5A) .
Alignment of the complex to trimeric Env via the V1V2 (Figure 3F ) confirmed the off-center footprint seen by EM ( Figure 2D ). Although direct VRC38.01 inter-protomer interactions were not observed, the Fab aligned closely to the N160 glycan of a neighboring gp120 protomer and the 9-residue disordered loop between positions N185 and S187 ( Figure S5C ). To probe these potential quaternary interactions, we engineered a glycan into the scaffold to mimic the neighboring N160 (scaffold insert position is shown in Figures 3C, 4I , and S5D). Although electron density observed for this engineered glycan was distal from the VRC38.01 epitope ( Figure S5E ), as N160 positioning is not precise, we were unable to rule out this interaction on the trimer. However, since VRC38.01 binds monomeric gp120 of several strains, N160 glycan binding to an adjacent protomer is probably not essential. The nine AAs following residue 185 in the V2 loop are disordered in available trimer structures and proximal to the framework 3 and CDRH1 of VRC38.01 ( Figure S5C ). However, mutagenesis suggested that this region did not affect VRC38.01, although other V2 bnAbs were marginally affected by some mutations within and proximal to this region ( Figure S5F and Table S4 ). Analysis of the docked model in Figure 3F suggested that three VRC38.01 Fabs could potentially occupy one HIV-1 trimer with no clashes (overlap cutoff > 0.4 Å ; Figure S5G ). The sub-saturating VRC38.01 stoichiometry ( Figures 2D and S4 ) may therefore stem from glycan or trimer structural heterogeneity (Liao et al., 2013) . Based on the distance of the modeled Fab C-termini, VRC38.01 is unique in being potentially able to use both IgG arms to engage the trimer. The large differences in VRC38.01 IgG and Fab neutralization potency ( Figure S4A ) and trimer affinity ( Figure S4B ) lend indirect support to this idea. In summary, the cocrystal reveals N156 and N160 glycan-dependence but also light-chain contacts and a possibility to engage the trimer with both IgG arms.
VRC38.01 Makes Side-Chain-to-Side-Chain Contacts at the V2 Apex VRC38.01 exhibits a near-charge-neutral 16 AA CDRH3, unlike other V1V2 NAbs that exhibit unusually long (> 24 AA) and anionic CDRH3s ( Figure 4A ) (Andrabi et al., 2015; Bonsignori et al., 2011; Doria-Rose et al., 2015; Gorman et al., 2016; McLellan et al., 2011; Walker et al., 2009 Walker et al., , 2011 . Although CH01 has greater breadth (53%) than its clonal variant CH03 (42%), we analyzed CH03 (AA sequence identity 83% in the VH and VL regions) due to the available V1V2-CH03 complex structure (Gorman et al., 2016) . A comparison to normal Ab repertoire sequences (Shi et al., 2014) revealed the CDRH3 length of VRC38.01 to be within normal range but other V1V2 NAbs to be outliers ( Figure 4B ). VRC38.01 exhibits a near-neutral CDRH3 charge, which is common in the repertoire ( Figure 4C ). In contrast, other V1V2 NAb CDRH3 loops are negatively charged due to prevalent Glu and Asp residues and sulfated tyrosines (Figures 4A and 4E and 4F) (legend continued on next page) Walker et al., 2009 Walker et al., , 2011 . Like other V1V2 NAbs, VRC38.01 substantially diverged from its germline (18%; Figures  4A and 4D) .
Inspection of CDRH3-V1V2 contacts revealed VRC38.01 to bind a site more distal from the trimer axis than bound by PG9 and CH03 ( Figure 4G ), consistent with its footprint ( Figure 2D ). Like other V1V2 NAbs, VRC38.01 bound the N156 and N160 glycans of strand B (Figures 4G and S5B) but made protein-protein contacts solely through Ab side-chain interactions, in contrast to PG9 and CH03, which made extensive main-chain parallel strand-strand interactions with strand C residues 167-171, proximal to the inter-protomer interface ( Figures 4H and S5A ). The CDRH3 and CDRH1 loops of VRC38.01 hydrogen bonded to side chains of strands A, B, and C, including two salt bridges formed with residues K168 and K171 of strand C and heavychain residues D31 and E97, respectively ( Figure 4H ). This side-chain-dependent binding shortens the distance the CDRH3 loop must penetrate the glycan shield to reach underlying protein, enabling a short CDRH3 to suffice ( Figures 4G-4I ).
VRC38.01 Contacts Glycans N156 and N160 and Strand C but Clashes with Glycan N130 VRC38.01 neutralized 30% of a diverse panel of 208 pseudoviruses ( Figure S6 and Table S1 ) at an IC 50 <50 mg/mL, comparable to HJ16 and better than 2G12 ( Figure S6A ). VRC38's GMT against the 62 sensitive viruses (0.46 mg/mL) was lower than that of CH03 (0.54 mg/mL), 2G12 (1.56 mg/mL), b12 (1.00 mg/ mL), 2F5 (1.63 mg/mL), and 8ANC195 (0.88 mg/mL) and was the same as HJ16 (0.46 mg/mL) ( Figure S6A ). VRC38.01 exhibited higher activity against 27 subtype A viruses (Table S1) , where breadth and median IC 50 were 52% and 0.043mg/mL, respectively (Table S1 ), though this increased activity was not seen on clade A recombinants (AG, AE, AC, AD) ( Figure S6B ). Overall, VRC38.01 exhibited modest potency and breadth.
Some bnAbs, including PG9 and PGT145, often plateau at < 100% neutralization, a phenomenon attributed in part to Env glycan heterogeneity (Doria-Rose et al., 2015; McCoy et al., 2015) . To see if VRC38.01 exhibits this phenomenon, we determined its maximum % neutralization ( Figure S6C ) against all 208 virus strains in Table S1 . To exclude weak neutralization, we only used data where IC 50 s were < 1 mg/mL. Among this set of neutralized viruses, 80% and 72% were neutralized at > 90% and > 95%, respectively. Similar patterns were observed for PG9 and PGT145. Sub-saturating neutralization was somewhat more pronounced for CAP256-VRC26.25 and was highly prevalent for CH01, where only 5% of viruses were neutralized at a plateau > 95%. In summary, like other glycan V1V2 NAbs, VRC38.01 exhibits sub-saturating neutralization of some viruses.
An analysis of key V1V2 residues of our 208-member virus panel suggest that its side-chain-based binding mode (Figures 4H and 4I) may limit VRC38.01's breadth ( Figure 5 ). Of the 146 VRC38.01-resistant strains, 135 related to variants at positions N130, N156, N160, K/R171, and Y173 (Figures 5A and 5B) . Despite the VRC38.01 light-chain contact with the poorly conserved N133 glycan of the WITO.33 strain ( Figures 3A and  3E ), many N133-lacking viruses were VRC38.01 sensitive. Variation at positions N160, K/R169, and K/R171 explained all 39 PG9-resistant viruses ( Figure S7 ). N156, N160, and K/R171 variants explained most CH03-resistant viruses, but 47 other resistant strains were unexplained ( Figure S7 ). Critical residues became apparent when resistance mutations were mapped onto mAb complexes ( Figure 5C ). VRC38.01 sensitivity was enhanced by a K/R171 salt bridge with Glu97 of the heavy chain and by Y173-induced reorienting of glycan N156 ( Figure 5C ). Conversely, the N130 glycan appeared to cause a light-chain clash ( Figure 5C ). PG9 sensitivity was enhanced by glycan binding and by electrostatic interactions between Lys/Arg169 and Tys100 g, as well as Lys/Arg171 and Asp100i ( Figure S7C ). CH03 sensitivity was also enhanced via glycan interactions and by a salt bridge formed between Lys/Arg171 and Glu30 of the heavy chain ( Figure S7D ).
Introducing the N130 glycan into eight viruses that naturally lack this glycan reduced VRC38.01 sensitivity of all eight viruses (by > 50-fold in seven cases) ( Figure 5D ) but had less impact on PG9 recognition and even less on PGT145 recognition, which neutralized a N130 glycan-bearing DU422.01 mutant more effectively ( Figure 5D ). These findings are consistent with the latter bnAbs targeting epitopes closer to the trimer vertex. Reciprocal removal of the N130 glycan increased VRC38.01 sensitivity of BaL.26 and 25711-2.4 by > 40-fold and CAAN.A2 by > 7-fold ( Figure 5E ). VRC38.01 achieved 47.5% neutralization of strain DU172.17 at 50 mg/mL but did not neutralize the parent virus ( Figure 5E ). Again, the effect of removing glycan was less pronounced for PG9 and PGT145, and in fact reduced PG9 sensitivity of the 25711-2.4 strain ( Figure 5E ). Autologous N90 donor viral sequences exhibited key contacts for VRC38 but had a sequon at N130 (Table S4 ) and were therefore VRC38.01-resistant. Upon N130D mutation, VRC38.01 reached 50% neutralization for three of viruses ( Figure S7E ). For the other five viruses tested, we detected increased VRC38.01 sensitivity that did not reach 50% at 100 mg/mL ( Figure S7F ).
Further mapping against strand A, B, and C mutants of the WITO.33 strain (Table S3 ) revealed sequon-disrupting S158A, N160K, and T162A mutations in strand B to reduce sensitivity to all four V1V2 NAbs (Table S3 ). Evaluation of the N156A mutant was complicated by its poor infection. Strand C mutations revealed K171 and Y173 to be critical for VRC38.01 but less so for other V1V2 NAbs. Analysis of BG505 and JR-CSF.JB strain mutants indicated similar VRC38.01 contacts (Table S3) . However, unlike WITO.33, a Y173A mutation rendered these strains (H) VRC38.01, PG9, and CH03 interactions with V1V2 strand C. VRC38.01 makes side-chain hydrogen bond contacts with K168 and K171 of strand C, N156 and S158 of strand B, and N133 of strand A. PG9 and CH03 make extensive main-chain parallel strand-strand interactions only with strand C. Side chain PG9 and CH03 contacts are shown in Figure S5A . (I) Summary of V1V2 mAb contacts. Aligned V1V2 sequences are shown with their VRC38.01 sensitivities. VRC38.01, CH03, and PG9 contacts are shown as closed circles (side chain contacts), open circles (main chain contacts), and starred circles (both side chain and main chain contacts). Strands A-D, the N133, N156, and N160 glycans and the site of an engineered N-linked glycosylation insert between strands B and C (residues 165 and 166) placed at the approximate location of the N160 glycan of the neighboring protomer. See also Figure S5 . completely PGT145 resistant, and a K171A mutation rendered JR-CSF, but not BG505, resistant to CH01. Overall, the complete disruption of VRC38 recognition by mutations at K171 or Y173 confirmed the strand C dependency of this antibody. Together, sequence analysis of sensitive and resistant viruses ( Figure 5 ) and mutation analysis (Table S3 ) indicated VRC38 resistance to be largely explained by a clash with glycan N130 or by a lack of key residues at positions 171 and 173 or by glycans at positions 156 and 160.
VRC38.01 Binding Tolerates Large Mannose Branches
The glycosylation inhibitor kifunensine prevents trimming of high mannose glycans, resulting in largely uniform Man 9 GlcNAc 2 structures. Pseudoviruses prepared with this inhibitor are often (Table S1 ) were rendered as logo plots, the height of each residue corresponding to its frequency. Residues and sequons (gly) linked with sensitivity (green) or resistance (red) with % conservation are shown. (legend on next page) resistant to V1V2 bnAbs (Doores and Burton, 2010), perhaps due to changes in apex folding or because of a loss of mAb contacts with glycan sialic acid termini in the absence of this inhibitor (Amin et al., 2013; Pancera et al., 2013) . We found that 83% (PG9), 92% (CH01), 94% (PGT145), and 69% (CAP256-VRC26.09) of kifunensine viruses were > 4-fold resistant (Table  S5 ), but only 38% were resistant to VRC38.01. This further distinguishes VRC38.01 from other V1V2 mAbs and is in line with structural evidence suggesting that it can accommodate large mannose branches.
B Cell Ontogeny of VRC38 Neutralization
A phylogenetic tree of all 11 lineage members was generated, rooted by a common inferred ancestor (IA, Figure 6A ). A variant with germline V-gene and J-gene reverted heavy (gH) and light (gL) chains that retained the mature CDRH3 was unable to neutralize (Table S1 ). However, hybrids consisting of mixed mature and reverted heavy-and light-chain partners, gHL and HgL, neutralized 19 and 18 strains of a 208-member panel, respectively (Table S1 ). Fourteen strains were sensitive to both hybrids, while others were neutralized by only one hybrid, indicating that both chains contribute to neutralization. When both the gHL and HgL Abs were effective, HgL potency was generally stronger, suggesting that the mature heavy chain plays a dominant role (Table S1 ). Overall, this suggests that VRC38 can neutralize $9% of heterologous strains with no maturation of the V gene of one chain.
VRC38 heavy-and light-chain maturation was modeled as shown in Figure 6 and Table S6 , respectively. S31D mutation likely occurred early in the VRC38 heavy chain ( Figure 6A and boxed starting at sequence I1 in Figure 6B ) and forms a salt bridge with a 97% conserved basic residue at position 168 (Figure 6C) . However, data above ( Figure 1E ) suggests that, unlike other V1V2 NAbs, this contact is not essential ( Figure S3B ). Indeed, a D31S mutant modestly reduced neutralization of 11 of the 14 strains tested ( Figure 6D ). Three exceptions were BG1168.01 and JR-FL.JB, which were both more sensitive to the D31S mutant, and ZA012.29, which was insensitive to either the parent mAb or D31S mutant.
VRC38.01 shared a branch with broadly neutralizing lineage members VRC38.06 and VRC38.07, whose breadth may relate to a S97E mutation acquired at intermediate I3 ( Figures 6A-6C ), that forms a salt bridge with K171 of strand C ( Figure 6C ). E97S reversion reduced VRC38.01 neutralization to a larger degree than the D31S mutant. The two reversions together led to a substantial loss in neutralization, suggesting that both contacts contribute to VRC38.01 neutralizing activity ( Figure 6D ). VRC38.09, which is almost as broad as the three members of the VRC38.01 branch but almost 3-fold lower in potency, lacks the S97E mutation. However, a S97E mutant increased its potency against 12 of the 14 strains ( Figure 6E ). Exceptions were the uniquely VRC38.09-sensitive strain X1632.S2.B10 ( Figure 1E ) and the BG1168.01 strain. The behavior of the latter mirrored the effect of the reciprocal mutation on VRC38.01 ( Figures 6D and  6E) . Overall, VRC38.09's breadth developed independently from other clones, and the sensitivity of some strains to this variant depended on different somatic mutations.
VRC38-like NAbs May Be Prevalent in HIV-Infected Donors
To analyze VRC38-like bnAb prevalence, we used neutralization fingerprinting Georgiev et al., 2013) to delineate bnAb specificities in a cohort of HIV-1-infected donors (Hraber et al., 2014) . VRC38-like specificities ( Figure 7A ) were common, appearing in $20% of plasmas, similar to the prevalence of PG9-like bnAbs. Analysis of the frequency of paired specificities ( Figure 7B ) revealed that VRC38-like and PG9-like signals were frequently paired with 10E8-like bnAbs-more frequently than 10E8-like pairings with other Abs. VRC38-like and PG9-like Abs also paired with each other, albeit at a much lower frequency than with 10E8. Overall, VRC38-like NAbs appear to be common in HIV-1 infection.
DISCUSSION
A growing number of recovered bnAbs now cover most of the Env-trimer surface. Many have unusual features that set a high bar for vaccine design and justify continued efforts to uncover new specificities. The VRC38 lineage provides a previously unknown solution for V1V2 apex binding, with potential advantages for vaccine elicitation. Abs with > 24 AA CDRH3s result from uncommon recombination events and, due to their typically autoreactive nature, may not survive B cell tolerance checkpoints (Briney et al., 2012a (Briney et al., , 2012b . In contrast, the length and charge of the VRC38 CDRH3 is within the normal repertoire range. The lack of CDRH3 tyrosine sulfation or prevalent anionic side chains further advance VRC38 as a tangible vaccine blueprint, although this possibility will require formal testing.
Our fingerprint analysis suggested that VRC38-like Abs may be as prevalent as PGT128-like or PG9-like Abs. We are now Table S6. mapping donor sera with VRC38-like signals and probing their B cells. Given its common features, VRC38-like NAbs might have been expected to be even more prevalent. However, an N130 glycan is found in > 60% of circulating viruses and is the single largest regulator of VRC38's breadth; N130 glycosylation may thus prevent VRC38-like bnAb development or facilitate escape. Accommodating glycan might therefore be a route to improved VRC38 breadth. We are now assessing additional donors and modifying our B-cell-probe strategy. For example, in a variation of the strategy in Figure 1C , B cells could be gated for positive binding to probes bearing a N130 glycan knock in mutation. It may also be useful to interrogate the N90 donor for VRC38 signatures by NGS and to probe samples from other donors that exhibit VRC38 fingerprint signatures. In a vaccine setting, N130 clash could be addressed using priming immunogens bearing an N130 ''glycan hole'' (Crooks et al., 2015) to promote VRC38-like NAb development and boosting with N130 glycancontaining immunogens to select for clones that can accommodate the glycan and thereby acquire greater breadth. Feasibility is supported by the observations that CD4bs-specific bnAb N6 evolved greater breadth by accommodating V5 loop glycans (Huang et al., 2016) and that the PGT121 family gained breadth by accommodating the N137 glycan (Garces et al., 2015) .
Like other V1V2 NAbs (except PGT145 that derives from VH1-8), VRC38 derives from a VH3 family V gene, the most common VH family in human B cell repertoires. Moreover, like other V1V2 bnAbs, VRC38 VH diverged < 20% from its germline. This contrasts with the higher ($30%-40%) divergence of CD4bs bnAbs, making the V1V2 an attractive vaccine target. Indeed, the marginal protective efficacy observed in the RV144 Thai vaccine trial was related to V1V2-specific Abs, albeit Abs that were non-neutralizing and may therefore have exerted antiviral pressure by other mechanisms (Liao et al., 2013) .
Some VRC38 binding requirements are akin to those of other V1V2 NAbs, including N156 and N160 glycan-dependent quaternary epitope preference and binding at less than 3:1 stoichiometry. In several other ways, however, VRC38 is unique. First, it binds farther away from 3-fold trimer axis, and both Fab arms of the VRC38.01 IgG may bind to a single trimer. It also exhibits a different binding mode that depends on CDRH1, CDRH3, and CDRL1 interactions with side chains of V1V2 strands A, B, and C, rather than main-chain interactions. This decreases the distance the CDRH3 must travel to penetrate the glycan shield. Since these contacts are conserved, VRC38 exhibits moderate breadth. Second, VRC38's CDRH3 exhibits a highly aromatic motif consisting of seven AAs (WFYHYYW), allowing it to accommodate glycans N156 and N160. Its unusual kifunensine resistance, along with structural data, suggest that it engages these glycans predominantly via their invariant stems. Thus, although glycan form variations may not affect VRC38, other V1V2 NAbs that depend, for example, on sialic acid contacts could be more prone to viral escape due to natural glycovariation (Amin et al., 2013; Pancera et al., 2013) . Alternatively, the larger Man 9 GlcNAc 2 structures promoted by kifunensine may distort packing at the trimer apex, perhaps having an impact on interprotomer binding by some V1V2 bnAbs (Julien et al., 2013), but not by VRC38 because it binds largely within one protomer. Unlike other V1V2 bnAbs (except CH01-CH04), VRC38.01's three CDRH3 tyrosines are not sulfated and lack anionic character. Specifically, ''YYD''-binding motifs (with both tyrosines carrying charged sulfates) of PG9 and CAP256-VRC26 are absent. Thus, unlike other V1V2 bnAbs, VRC38.01 binding is not heavily dependent on electrostatic interactions.
Although VRC38.01 depends on residues K171 and Y173 of strand C, its partial K168 independence uniquely allows it to neutralize strains that are insensitive to other V2 mAbs. While K171 makes a clear electrostatic interaction with VRC38.01, Y173 may indirectly contribute by reorienting the N156 glycan. The lack of sensitivity of clade D viruses to VRC38.01 is explained by the fact that they typically lack the critical K/R171 and Y173 contacts. The higher clade A breadth of VRC38.01 was surprising, considering the donor's infection with a clade B virus and North American origin . However, clade A preference is also true for other V1V2 bnAbs, albeit those derived from African origin. However, although VRC38.01 breadth against clade A and clade A hybrid viruses was relatively high, it did not exceed that against the infecting clade B.
The cells from which the VRC38 lineage was cloned were sampled many years after infection, making it difficult to trace B cell ontogenies. A common unmutated ancestor and intermediates were nonetheless inferred from the 11 Ab sequences derived from the single time point. Neutralization by the V gene reverted VRC38.01 Ab and hybrid Abs with mature chains indicated both chains to contribute to neutralization, with the heavy chain making a greater contribution. Two affinity-matured residues on the heavy chain (S31D and S97E) that form salt bridges were present in the three broadest clones. The neutralizing activity of the gHL variant suggests that while these interactions are not critical, they increase both breadth and potency.
One variant, VRC38.09, neutralized a virus that was insensitive to the VRC38.01 branch. Another virus was uniquely neutralized by the VRC38.14 variant heavy chain when paired with VRC38.01 light chain. Combining the number of viruses neutralized by all variants brought the VRC38 lineage breadth to 48%. It is unclear if a pathway could be found to neutralize these strains (and perhaps more) by a single VRC38 clone, especially since we only have access to one time point in this donor and thus can only approximate how the lineage might have evolved.
Our success in recovering VRC38 may in part be due to extensive VLP and B cell probe development. The broadest lineage member, VRC38.01, was identified using trimer VLPs as probes, and others were then isolated using SOSIP trimers. Thus, VLPs may complement existing B cell probes (Doria-Rose et al., 2015; Sok et al., 2014; van Gils et al., 2016) . The high frequency of NAb clones in the VLP sort (2 out of 92; 2.2%) was consistent with specific staining. Nevertheless, certain suboptimal aspects of VLPs could be improved. Trimer VLPs imparted smeared staining in which VRC38.01 and VRC38.02 were relatively dim on the GFP axis, as opposed to a clearly separated positive population commonly seen with soluble SOSIP trimers. We are currently investigating alternative conjugation technologies (Mengistu et al., 2015) to tag VLPs with brighter fluorophores to enhance positive stain separation from background. Our observation that VRC38.01 contributes only partially to N90 serum breadth suggests that other bnAbs exist in this donor that we are now trying to recover.
In summary, a VLP probe recovered a VRC38 NAb lineage targeting the trimer apex without protruding binding loops by a previously unrecognized mechanism involving side-chain-to-sidechain interactions that reduced the distance an Ab loop must traverse the glycan shield. The genetic, functional, and structural analysis of this lineage, together with serological fingerprint analysis, suggest that similar NAbs may be relatively common during HIV-1 infection and may thus be amenable to vaccine elicitation.
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for HIV/AIDS Vaccine Immunology (CHAVI) and NIAID, as previously published (Hraber et al., 2014) was used for fingerprinting analysis. CAPRISA sample donors signed informed consent to participate in protocols approved by research ethics committees of the University of Kwazulu-Natal, the University of Cape Town, and the University of the Witwatersrand. CHAVI sample donors signed informed consent and participated in protocols approved by the Kilimanjaro Christian Medical Centre Research Ethics Committee, the Tanzania National Institutes for Medical Research Ethics Coordinating Committee, the Institutional Review Boards of the London School of Hygeine and Tropical Medicine and Duke University, and the NIH Institutional Review Board. Serum from chronically infected donor 1686, who signed informed consent to participate in protocol IRB-15-002-JB approved by the San Diego Biomedical Research Institute's Institutional Review Board, was previously shown to broadly neutralize via epitope(s) overlapping the CD4 binding site (Binley et al., 2008) . PBMCs with no donor identifiers were also obtained from seronegative subjects for bait optimization; these donors participated in protocols approved by the NIH Institutional Review Board.
Cell Lines
Human embryonic kidney (HEK)-derived 293T, HEK293S N-acetylglucosaminyltransferase I-negative (GnTI-), and HeLa-derived TZM-bl cells were maintained in complete Dulbecco's Modified Eagle Medium (herein referred to as cDMEM) containing highglucose Dulbecco's Modified Eagle Medium (DMEM, Thermo Fisher), 1X Penicillin-Streptomycin (Pen Strep, Thermo Fisher) and 10% fetal bovine serum (FBS, Gemini Bio Products) at 37 C/5% CO 2 . Canine thymus-derived CF2Th.CD4.CCR5 cells were maintained in DMEM containing 1X Pen Strep, L-glutamine, 500 mg/ml G418, 150 mg/ml Hygromycin, and 10% FBS at 37 C/5% CO 2 . FreeStyle 293F and Expi293F cells (both Thermo Fisher) were maintained in Freestyle 293 Expression Medium and Expi293 Expression Medium, respectively, at 37 C/10% CO 2 with shaking at 120 RPM. Human Burkitt's B cell lymphoma-derived Ramos cells were maintained in either DMEM containing 15% FBS and 1X Pen Strep or Roswell Park Memorial Institute 1640 medium (RPMI 1640, Thermo-Fisher) containing 10% FBS and 1X Pen Strep at 37 C/5% CO 2. In some cases, Ramos cells were engineered to stably express mature B cell receptors (BCR) IgM versions of VRC01, PGT145, and PGT128.
METHOD DETAILS
Anti-HIV-1 Env Monoclonal Abs
MAbs were obtained from the NIH AIDS Reagent Repository or from their originators. Further information can be found in the HIV Molecular Immunology Database (http://www.hiv.lanl.gov/) and in ref (Burton and Hangartner, 2016) . MAbs included the following (originators given in parentheses): 2G12 (H. Katinger), directed to a glycan cluster on gp120; 39F and CO11 (J. Robinson), directed to the gp120 V3 loop; b12 (D. Burton), VRC01, VRC07-G54W, VRC13 (J. Mascola) and HJ16 (A. Lanzavecchia) directed to epitopes that overlap the CD4bs; PGT121, PGT125 and PGT128 (D. Burton) directed to epitopes involving the base of the V3 loop of gp120 and the N332 glycan; PG9, PG16, PGT145, PGDM1400 (D. Burton), CH01 and CH03 (B. Haynes) and CAP256.01-33 (J. Mascola), directed to quaternary, glycan-dependent V1V2 loop-directed epitopes; PGT151 (D. Burton), 35O22 (M. Connors), and 8ANC195 (M. Nussenzweig), directed to the gp120/gp41 interface; 10E8 (M. Connors), 2F5 and 4E10 (H. Katinger), directed to the gp41 membrane-proximal ectodomain region (MPER).
Plasmids and Mutagenesis
Plasmid pCAGGS was used to express JR-FL SOS E168K gp160DCT , featuring a 3 amino acid gp41 cytoplasmic tail, ''SOS'' mutations (A501C and T506C) to introduce a disulfide bond between gp120 and gp41 (Binley et al., 2000) and an E168K mutation to ''knock in'' V1V2 bnAb epitopes (Doores and Burton, 2010; Tong et al., 2012) . Various Env expression plasmids were used to pseudotype viruses for neutralization assays and to express soluble gp140 glycoproteins, including uncleaved (UNC) YU2 gp140 foldon (gp140F) and BG505.DS.T332N.SOSIP.664 gp140 trimers (termed BG505 SOSIP trimers elsewhere for brevity) that feature the stabilizing 201C-433C disulfide (DS) mutation (Kwon et al., 2015) . Some clones featured a C-terminal Avi tag (GLNDIFEAQKIEWHE) to enable biotinylation and fluororphore-streptavidin complexing (Doria-Rose et al., 2015) . A codon optimized WITO strain V1V2 1FD6 scaffold was designed based on a previous construct (McLellan et al., 2011) and features an artificial N-terminal secretion signal (MRPTWAWWLFLVLLLALWAPARG), a C-terminal HRV3C cleavage site (GLEVLFQGP) followed by an 8-His tag and an engineered N-linked glycosylation site between strands B and C (residues 165 and 166) at the approximate location of the N160 glycan from the neighboring protomer. Env-deficient sub-genomic plasmids pNL4-3.Luc.R-E-and pSG3DEnv were described previously (Li et al., 2005) . Plasmids pMV-2024 and pMV-ERV express full-length SIVmac251 (BK28) and MLV Gag, respectively. Plasmid pMV-0932 that expresses HIV-1 Rev was co-expressed whenever VLPs were produced using SIV or MLV Gag (Crooks et al., 2015) . Plasmids pGag-GFP and pGag-RFP express full-length HIV-1 p55 Gag fused to eGFP and mCherry fluorphores, respectively, that for convenience are referred to as GFP and RFP throughout this study (Gomez and Hope, 2006) . mAb heavy and light chain genes (in many cases codon optimized) were inserted into pVRC8400 to express IgG in Freestyle 293F or Expi293F cells, followed by protein A purification. In some cases, heavy chain plasmids were modified to add a C-terminal streptactin II tag (GGPGSAWSHPQFEKGGGSGGGSGGSAWSHPQFEK), a HRV3C recognition site (LEVLFQ/GP) inserted after K235 of the heavy chain and/or M428L/N434S mutations (indicated by a ''-LS'' suffix) (Zalevsky et al., 2010) , to improve neonatal Fc receptor binding and in vivo half life.
Ramos-IgM Cell Line Production
Ramos cells were engineered to stably express mature B cell receptors (BCR) IgM versions of VRC01, PGT145, and PGT128.by lentiviral transduction of the cells using FEEKW-vectored light chain and IgM heavy chain-expressing lentiviruses. BCR-positive cells were identified by staining with both PE-conjugated mouse anti-human-kappa/lambda (BD Biosciences) and anti-human-IgM (Biolegend) by flow cytometry and sorted using a FACS Aria (BD Biosciences). Cells were amplified, assessed for BCR expression as before, and resorted for highest-staining cells if needed.
VLP Production
VLPs were produced by co-transfecting 293T or Freestyle 293F cells with plasmids expressing Env, Gag, and Rev (Crooks et al., 2015) . Fluorescent VLPs were produced by also cotransfecting plasmids pGag-GFP or pGag-RFP. Two days later, supernatants were collected, filtered, precleared by centrifugation at 450Xg for 5 min, and concentrated either by tangential flow filtration or by centrifugation at 50,000Xg in a Sorvall SS34 rotor. ''Trimer-VLPs'' were made by digesting with 1 mL each of 1mg/ml proteinase K, subtilisin, and trypsin, and 1 mL of 2mg/ml chymotrypsin (Crooks et al., 2011; Tong et al., 2012) . pNL4-3.Luc.R-E-based fluorescent VLPs were inactivated using 1mM aldrithiol (AT-2) before use as baits (Crooks et al., 2015) . RFP-labeled ''Bald-VLPs'' were produced by co-expressing pMV-2024 (expressing SIV Gag) and pGag-RFP plasmids.
Soluble Env Protein Production
Trimeric Env constructs were expressed in various types of 293 cells and then purified by previously published methods (Bhiman et al., 2015; Doria-Rose et al., 2015; Stewart-Jones et al., 2016) . For BG505.T332N.SOSIP proteins used for flow cytometric cell sorting, Avi-tagged proteins were biotinylated using the BirA Biotin-Protein Ligase Bulk Reaction Kit (Avidity, LLC) under the following conditions and reagents from the kit: 25 mL of 10X Biomix A, 25 mL of 10X Biomix B, 20 mg of BirA protein, and 180 mL of Avi-tagged SOSIP protein, incubated for 5 hr at 30 C with constant agitation. The mixture was buffer exchanged into SOSIP buffer containing 5mM HEPES, 150mM NaCl, and 0.02% NaN 3 in 30,000 MWCO Amicon Ultra-15 centrifugal filter units (EMD Millipore) over 5 rounds of spinning at 3000Xg, 4 C. Biotinylated SOSIP was then conjugated with streptavidin, R-phycoerythrin (SA-PE, Thermo Fisher) at a 1.17 SA-PE:SOSIP weight ratio (determined empirically). Briefly, biotinylated SOSIP was mixed with 1/5 the final volume of SA-PE and incubated for 20 min at 4 C with gentle rotation. Subsequent 1/5 increments of SA-PE were then added with 20 min incubations in between each addition. APC-conjugated YU2 gp140 foldon (gp140F) protein was biotinylated and conjugated to SA-allophycocyanin (SA-APC, Thermo Fisher) in the same manner at a 1.8 gp140F:SA-APC weight ratio (determined empirically).
V1V2 regions of various strains (residues 126-196, HXB2 numbering) were scaffolded onto a core variant of protein G (PDB: 1FD6) and were produced in HEK293S GnTI-cells and purified over Ni-NTA superflow resin (QIAGEN), then digested with HRV3C (Novagen) and purified over a 16/60 S200 size exclusion column (McLellan et al., 2011; Ross et al., 2001) .
HIV-1 Env-pseudotyped Virus Production
Pseudoviruses for use in TZM-bl neutralization assays were produced in 293T cells by cotransfection of a pSG3DEnv backbone plasmid and a full HIV-1 Env gp160-encoding plasmid (Li et al., 2005) . Briefly, 2X10 6 cells in 20ml cDMEM were seeded in T75 flasks the day prior to cotransfection. For transfection, 40 mL of FuGene 6 reagent (Promega, Fitchburg, WI) was diluted into 800 mL of roomtemperature Opti-MEM I reduced serum medium (Thermo Fisher), followed by addition of 10 mg of pSG3DEnv backbone plasmid. 3.3 mg of HIV Env plasmid was then added to the mixture, mixed, and incubated for 30 min at room temperature. Transfection mixture was then added to media of previously seeded 293T cells in the T75 flask and then distributed evenly on cells. The following day, media was replaced with 20ml fresh cDMEM. Virus was harvested the following day by filtering cell supernatants with 0.45 mm Steriflip units (EMD Millipore) and aliquotted. Pseudoviruses for use in CF2 cell assays were produced in 293T cells by cotransfecting pNL4.3.Luc.R-E backbone plasmid and Env-expressing pCAGGS plasmid using polyethylenimine (PEI) Max (Polysciences). Briefly, 5X10 6 cells were seeded on a 15cm tissue culture dish one day prior to transfection. On the day of transfection, 10 mg of pNL4.3.Luc.R-E and 10 mg of Env plasmid were mixed in 2ml of serum-free DMEM. 40 mL of 1mg/ml PEI Max (DNA:PEI ratio 1:2) was added and incubated at room temperature for 30 min. 11ml of cDMEM was then added to the transfection mixture. 293T cells were washed with PBS, and transfection mixture was added to the cells and distributed evenly. Following a 2 hr incubation at 37 C, culture dishes were washed with PBS, and 25ml of cDMEM was added to the cells for a 48 hr incubation at 37 C. Following incubation, virus was harvested by pelleting cell culture supernatant at 450Xg and filtering supernatant through a 0.8 mm filter.
For pseudoviruses containing point mutations, mutations were introduced into full HIV-1 Env-encoding plasmids using the QuickChange II Site-Directed Mutagenesis Kit (Agilent Technologies) according to the manufacturer's directions. For pseudoviruses produced under conditions containing kifunensine, 25 mM kifunensine was added at the time of plasmid cotransfection and replenished during the media change.
B Cell Sorting of Env Trimer-specific Clones
Frozen PBMCs ($5X10 7 cells) were thawed in cDMEM containing 50 U/ml of benzonase (Novagen). For flow cytometric sorting, B cells were first enriched by negative magnetic bead selection using the Human B Cell Isolation Kit II (Miltenyi Biotec), then washed in PBS, resuspended in LIVE/DEAD Fixable Violet Dead Cell Stain (Thermo Fisher) and incubated for 30 min at 4 C. Cells were washed once in PBS and multicolor staining was performed using a panel of fluorophore-labeled mAbs directed to CD3 (APC-Cy7, clone SK7), CD8 (Brilliant Violet 711, clone RPA-T8), CD14 (Brilliant Violet 605, clone M5E2), CD19 (PE-Cy7, clone HIB19) and human IgG (fluorescein isothiocyanate [FITC] or Alexa Fluor 680, both clone G18-145). All mAbs were obtained from BD Biosciences except for those directed to CD8 and CD14 (Biolegend) and the anti-IgG-Alexa 680 Ab (custom-conjugated at the Vaccine Research Center, National Institutes of Health). Cells were also stained with fluorophore-tagged VLPs, BG505 SOSIP trimers or YU2 gp140F. All staining was performed at 4 C for 30 min, followed by two PBS/10% FBS washes and resuspension in PBS. Single Cell RT-PCR of Ig Genes RT-PCR amplification of IgG heavy and light chain genes was performed as described previously (Doria-Rose et al., 2015) . 96-well plates containing single sorted cells were initially frozen at À80 C and thawed to maximize liberation of cellular mRNA. Total mRNA in each well of the 96-well plates was reverse transcribed using 200U/well Superscript III reverse transcriptase (Thermo Fisher), 2 mL of 10mM dNTP mix (Bioline) and 3 mL of 150 ng/ml random hexamers (Gene Link) under the following cycling parameters: 42 C 10 min, 25 C 10 min, 50 C 60 min, 94 C 5 min, and 4 C hold. First strand cDNA was amplified in a 2-step multiplex nested PCR in which the first step used either mixed g-, l-, or k-chain-specific primers (listed in (Doria-Rose et al., 2015) . 50 mL k-chain amplification reactions were performed using the QIAGEN HotStarTaq Plus DNA Polymerase Kit as follows (all reagents from HotStarTaq Plus kit unless otherwise noted): 1X QIAGEN PCR Buffer, 200 mM dNTP mix (Bioline), 500 mM MgCl 2 , 1 mL of 50 mM 1 st round forward primer mix (5 0 L-Vk mix), 1 mL of 25 mM 1 st round reverse primer (3 0 Ck 543), 2U HotStarTaq Plus, and 5 mL of first-strand cDNA, under the following cycling parameters: 95 C 5 min; 50 cycles of 95 C 30 s, 58 C 30 s, 72 C 1min; 72 C 7 min; and 4 C hold. 40 mL g-chain and l-chain amplification reactions were performed similarly as follows: 1X QIAGEN PCR Buffer, 125 mM dNTP mix (Bioline), 1.4mM MgCl 2 , 0.2 mL of 50 mM 1 st round forward primer mix (G1, G2, or G3 mix for g-chain and 5 0 L-VL-RL mix for l-chain), 0.2 mL of 25 mM 1 st round reverse primer (3 0 CgCH1 for g-chain and 3 0 Cl for l-chain), 2U HotStarTaq Plus, and 3 mL of first-strand cDNA. g-chains were amplified under the following cycling parameters: 94 C 5 min; 50 cycles of 94 C 30 s, x C 30 s, 72 C 55 s; 72 C 10 min; and 4 C hold, where x = 54 C for G1 mix, 48 C for G2 mix, and 52 C for G3 mix. l-chains were amplified under the following cycling parameters: 95 C 5 min; 50 cycles of 95 C 30 s, 50 C 30 s, 72 C 1min; 72 C 7 min; and 4 C hold. The second multiplex PCR step used mixed chain-specific primers that were complementary to regions slightly upstream and downstream of the first step forward and reverse primers, respectively. 50 mL g-, k-and l-chain amplification reactions were performed using the QIAGEN HotStarTaq Plus DNA Polymerase Kit as follows (all reagents from HotStarTaq Plus kit unless otherwise noted): 1X CoralLoad PCR Buffer, 200 mM dNTP mix (Bioline), 1X Q Solution, 1 mL of 50 mM 2 nd round forward primer mix (5 0 L-VH mix + 5xwl-VH mix for g-chain, 5 0 L-Vk-MS mix for k-chain, and 5 0 L Vl mix for l-chain), 1 mL of 25 mM 2 nd round reverse primer (3 0 IgGint for g-chain, 3
0 Ck 494 for k-chain, and 3 0 XhoI Cl for l-chain), 2U HotStarTaq Plus, and 3.5 mL 1 st round PCR product. g-chains were amplified under the following cycling parameters: 95 C 5 min; 50 cycles of 95 C 30 s, 58 C 30 s, 72 C 1min; 72 C 7 min; and 4 C hold. k-chains were amplified under the following cycling parameters: 95 C 5 min; 50 cycles of 95 C 30 s, 52 C 30 s, 72 C 1min; 72 C 7 min; and 4 C hold. l-chains were amplified under the following cycling parameters: 95 C 5 min; 50 cycles of 95 C 30 s, 60 C 30 s, 72 C 1min; 72 C 7 min; and 4 C hold. 10 mL of each second round PCR product was loaded into 1% ethidium bromide-stained pre-cast gels (Embi Tec, San Diego, CA) and run at 120 V. Gels were visualized under ultraviolet light, and second round PCR products from wells where PCR-amplified bands were obtained were selected for sequencing by ACGT, Inc (Wheeling, IL). Alignments of sequences to germline V-, (D-), and J-genes and junctional analyses were performed using IMGT/V-QUEST (www.imgt.org). Clones of interest were identified by several criteria, including substantial germline mutations (> 10%) indicating a history of affinity selection, long CDRH3 loops and by repeated recovery in separate wells. Selected PCR products were cloned into pVRC8400 to construct heavy chain-and light chain-expressing plasmids for mAb expression and purification. mAb and Fab Production mAbs were expressed by cotransfection of Expi293F or Freestyle 293F cells (Thermo Fisher) with heavy chain-and light chain-expressing plasmids according to the cell manufacturer's directions. Following a 6-day incubation, transfection mixtures were pelleted by centrifugation and filtered through 0.22 mm Stericup filter units (EMD Millipore). Filtered supernatant was applied to a column containing a 1ml bed of Protein A Sepharose Fast Flow (GE Healthcare) equilibrated with Pierce Protein A IgG Binding Buffer (Thermo Fisher). The column was washed with Protein A IgG Binding Buffer, and mAb was eluted with Pierce IgG Elution Buffer (Thermo Scientific) and collected in a 1:10 volume of 1M Tris pH 8 solution. Antibodies were buffer-exchanged in PBS using 10,000 MWCO Amicon Ultra-15 centrifugal filter units (EMD Millipore) over three rounds of spinning.
For Fab production, the cleavage site (GLEVLFQGP) for the 3C protease of human rhinovirus (HRV3C) was inserted into the hinge region of the Ab heavy chain expression plasmid. Following expression and purification of mAb, the protein was subjected to HRV3C protease. Products were purified by gel filtration, and Fab fragments were collected for use in assays.
Biotinylation of mAbs
MAbs were biotinylated using EZ-Link Sulfo-NHS-Biotin (Thermo Fisher). Briefly, mAb was concentrated to 2-2.5 mg/ml (200-250 mL volume) and mixed with 15 mL of 50mg/ml Blue Dextran. mAb:Dextran mixture was applied to a Sephadex G25, NAP-5 column (GE Healthcare) previously washed 5X with 0.1M bicarbonate buffer (100mM NaHCO 3 , pH 8.4). Antibody was eluted with 0.1M bicarbonate buffer, and the blue fraction containing mAb was collected. EZ Link Sulfo-NHS-Biotin (prepared as a 10mg/ml solution with dimethylsulfoxide) was added at 80 mg per 1mg mAb ratio and allowed to mix by rotating for 4 hr at room temperature. Biotinylated mAb was then loaded onto a Sephadex G25, PD-10 desalting column (GE Healthcare) previously washed 5X with a storage buffer containing 10mM Tris, 150mM NaCl, 0.1% NaN 3 , pH 8.2. mAb was eluted with storage buffer, and the blue fraction containing biotinylated mAb was collected.
ELISAs with Recombinant VLPs, gp120 and gp140 Briefly, Immulon II plates were coated with either 20x concentrated VLPs (Tong et al., 2012) , 5mg/ml recombinant gp120 monomer, or 5mg/ml gp140 trimers overnight at 4 C. Plates were washed with PBS twice and blocked. For VLP ELISA, blocking buffer was 4% BSA in 10% FBS/PBS, and for gp120 or gp140 ELISAs, blocking buffer was 4% milk in 0.05% Tween20/PBS. After 1h of blocking at room temperature and 2 washes with PBS or PBS containing 0.1% Tween 20 (PBS-T), serially diluted sera or mAbs were added in the following reaction buffers: 2% BSA in 10%FBS/PBS for VLP ELISA and 2% milk in PBS-T for gp120 or gp140 ELISAs. Plates were incubated for 1 hr at 37 C followed by 2 PBS or PBS-T washes. Species-specific alkaline phosphatase anti-Fc conjugates (Accurate) diluted in the corresponding reaction buffers at 1:5,000 were then added and plates were incubated at 37 C for 30 min. After a 4X wash with distilled H 2 O, 50 mL of SigmaFAST p-nitrophenyl phosphate tablets (Sigma, St. Louis, MO) dissolved in distilled H 2 O was added and incubated for 1 hr at room temperature in the dark. Reaction was stopped by adding 10 mL of 3N NaOH and detected at 405nm.
ELISAs using SOSIP gp140 trimers, gp140F, gp120 monomers, and V1V2 scaffolds were performed on Reacti-Bind 96-well polystyrene plates (Pierce). Briefly, plates were coated with 2 mg/ml of monomer/trimer in PBS overnight at 4 C. Following 6 washes with PBS-T and blocking for 1 hr at 37 C with B3T buffer (150 mM NaCl, 50 mM Tris-HCl, 1 mM EDTA, 3.3% FBS, 2% bovine serum albumin, 0.07% Tween 20, and 0.02% thimerosal), 5-fold serially diluted sera or mAbs were added in B3T buffer. After a 1 hr incubation at 37 C and 6 washes with PBS-T, plates were incubated with HRP-conjugated anti-human IgG, Fcg fragment-specific antibody (Jackson ImmunoResearch, West Grove, PA) diluted 1:10,000 in B3T buffer for 1 hr at 37 C. After 6 washes with PBS-T, SureBlue TMB Substrate (KPL) was added, incubated for 10 min, and the reaction was stopped with 1N H 2 SO 4 before measuring binding at 450nm.
Competitive VLP ELISAs was performed similarly to regular VLP ELISAs. Plates were coated, washed, and blocked in the same manner. After blocking, plates were washed twice with PBS, and 25 mL of competitor antibody was added at a fixed concentration. Following a 10 min incubation at 37 C, titrated biotinylated or Strep II-tagged mAbs were added and incubated for an additional hour at 37 C. After 2 washes with PBS, conjugates were added as follows: 1:300-diluted streptavidin-alkaline phosphatase (Vector) for biotinylated antibodies or 1:500-diluted streptactin-alkaline phosphatase (IBA Life Sciences) for Strep II-tagged antibodies. Plates were washed with distilled H 2 O 4 times, 50 mL of SigmaFAST p-nitrophenyl phosphate tablets (Sigma) dissolved in distilled H 2 O water was added, and plates were incubated for 1 hr at room temperature in the dark. Reaction was stopped by adding 10 mL of 3N NaOH before measuring binding at 405nm.
Measuring Probe Binding to mAb-Coated Beads
CompBead Anti-Mouse Ig, k (BD Biosciences) were coated with mAbs for antigenic analysis of HIV-1 Env proteins and trimers. Briefly, 1ml of particles (beads) was pelleted at 1000Xg for 5 min, and supernatant was aspirated. Beads were resuspended in 1ml 0.5% bovine serum albumin (BSA) in PBS. 1 mg of Purified Mouse Anti-Human Ig k Light Chain antibody (BD Biosciences) was added and allowed to incubate for 30 min at room temperature. 2ml of 0.5% BSA/PBS was added, beads were pelleted at 1000Xg for 5 min, and supernatant was aspirated. Beads were resuspended in 1ml of 0.5% BSA/PBS, and 1 mg of mAb was added, mixed, and incubated for 30 min at room temperature. 2ml of 0.5% BSA/PBS was added, beads were pelleted at 1000Xg for 5 min, and supernatants were aspirated. Beads were resuspended in 1ml 0.5% BSA/PBS for short-term storage of up to 1 week at 4 C. For staining, 50 mL of antibody-coated beads were mixed with different amounts of streptavidin-conjugated HIV-1 Env protein or trimer, incubated with 30 min at 4 C, and washed with 3ml of PBS. Beads were pelleted at 1000Xg for 5 min, supernatants were aspirated, and beads were resuspended in 300-500 mL PBS for flow cytometric analysis.
Neutralization Assays Using TZM-bl Cells 10 mL of 5-fold serially diluted mAbs or patient serum in cDMEM was incubated with 40ul of diluted HIV-1 Env-pseudotyped virus and incubated for 30 min at 37 C in a 96-well tissue culture plate. 20 mL of TZM-bl cells (10,000 cells/well) with or without 70 mg/ml DEAEDextran was then added and incubated overnight at 37 C. Each experiment plate also had a column of cells only (no Ab or virus) and a column of virus only (no Ab) as controls for background TZM-bl luciferase activity and maximal viral entry, respectively. The following day, all wells received 130 mL of fresh cDMEM and were incubated overnight at 37 C. The following day, media was aspirated from wells, and 50 mL of 1X Cell Culture Lysis Reagent (Promega) in distilled H 2 O was added to cells. Lysates were shaken at 600RPM for 15 min, and 30 mL of lysate was transferred to OptiPlate black plates (Perkin Elmer). Luminometry was performed on a Perkin Elmer Model #1420-061 luminometer using the Promega Luciferase Assay System reagent (reconstituted in buffer provided with the kit,
